HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J cuts jobs and invests in core brands

This article was originally published in The Rose Sheet

Executive Summary

Johnson & Johnson will eliminate 6% to 7% of its global workforce in response to external pressures on the health care industry, the company announced Nov. 3. Cuts will come across all three of the company's core businesses: consumer products, pharmaceuticals and medical devices. Eliminations will take place globally, but mostly outside the U.S., and will reduce "layers of management," CEO William Weldon said during a same-day conference call. The plan will yield pre-tax cost savings of $1.4 bil. to $1.7 bil. in 2011, with $800 mil. to $900 mil. expected to be achieved in 2010. J&J plans to invest the savings in key innovation opportunities and core businesses, including "iconic brands," such as mouthwash Listerine and skin care lines Aveeno and Neutrogena, Weldon said

You may also be interested in...

Neutrogena introduces online holiday shopping destination

Johnson & Johnson brand launches Holiday.Neutrogena.com, an "easy-to-use beauty gifting resource offering a range of top-selling and favorite cleansing, acne, anti-aging and body care products," J&J announces. Purchases from the collection can be made for a limited time through January 2010. Products include Complete Acne Therapy System for $19.99, Neutrogena Wave Power Cleanser for $12.99 and Oil-Free Acne Wash Pink Grapefruit Foaming Scrub for $7.99. J&J's recent job cuts will result in investments in core brands, such as Neutrogena (1"The Rose Sheet" Nov. 9, 2009)

Expectations Are High For New EMA Boss

Emer Cooke seems set to take over as head of the European Medicines Agency – one of the world's most powerful regulatory bodies – before the end of the year. We report on the reaction of a range of pharmaceutical sector stakeholders to her nomination.

Clif Bar Claims In Google Ads Clipped In Accelerated Review Of Kind Challenge

Clif Bar didn’t convince National Advertising Division a challenge by Kind is too “complex” for the SWIFT forum. NAD attorneys determined Clif didn’t support its claims of sustained energy and “better” performing ability.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts